Clinical trial
A Phase 1a/1b Multicenter, Open Label, Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CWP232291 Administered Intravenously Either Alone or in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Myeloma (MM)
NCT02426723 is registered in ClinicalTrials.gov with JW Pharmaceutical as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1a/1b Multicenter, Open Label, Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CWP232291 Administered Intravenously Either Alone or in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Myeloma (MM)
- Lead sponsor
- JW Pharmaceutical
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- October 19, 2015
- Completion date
- October 26, 2018
- Enrollment
- 25 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.